d VKA had been usually reported to possess more co-morbidities.TABLE 1 The incidence rates and incidence rate ratios of thrombotic and bleeding outcomesRecurrent venous thromboembolism or stroke/systemic thrombosis Incidence price per 100 person-years (95 CI) 3.83 (three.08.76) 6.81 (5.53.37) 1.16 (0.86.59) 1.18 (0.67.08) 0.96 (0.78.16) Important bleeding Incidence rate per one hundred person-years (95 CI) 1.63 (1.17.28) two.97 (1.21.27) two.74 (1.68.48) three.61 (1.78.31) 0.75 (0.59.96)Population Venous thromboembolism Atrial fibrillationAnticoagulant Direct oral anticoagulants Vitamin K antagonists Direct oral anticoagulants Vitamin K antagonistsIncidence rate ratio (95 CI) 0.78 (0.48.27)Incidence rate ratio (95 CI) 0.72 (0.54.96)Conclusions: Individuals with morbid obesity on fixed-dose DOAC did not appear to have worse outcomes in comparison with VKA. Even so,the strength of proof remained low offered that benefits were mostly observational with higher danger of confounding.ABSTRACT921 of|PB1255|Statins for Venous Occasion Reduction in Sufferers with Venous Thromboembolism: A Randomized Controlled Pilot Trial Assessing Feasibility A. Delluc1; W. Ghanima2; M. Kovacs3; S. Shivakumar4; S. Kahn5; P.M. Sandset6; C. Kearon7; M. RodgerOutcomes Clinically relevant nonmajor bleeding, n ( ) Main muscle toxicity (CK10ULN), n ( ) Muscle-related adverse events, n ( )Rosuvastatin (n = 155) two (1.three)Control (n = 157) 1 (0.6)P value1 (0.six) 11 (7.1)0 1 (0.6)1 0.Ottawa Hospital Research Institute, Ottawa, Canada; 2Ostfold4Hospital, Ostfold, Norway; 3University of IL-12 Inhibitor Synonyms Western Ontario, London, Canada; Dalhousie University, Halifax, Canada; McGill University, Montreal, Canada; 6University of Oslo, Oslo, Norway; 7McMaster University, Hamilton, Canada Background: Statins may well reduce the risk for recurrent venous thromboembolism (VTE), even so, no randomized trials have explored this hypothesis. Aims: To figure out feasibility of recruitment of a bigger trial of secondary VTE prevention with rosuvastatin. Strategies: Individuals using a newly diagnosed symptomatic proximal deep vein thrombosis and/or pulmonary embolism, receiving common anticoagulation, had been randomly allocated to COX-2 Modulator web adjuvant rosuvastatin 20 mg after each day for 180 days or no rosuvastatin for 6 months. Final results: Between November 2016 and December 2019, 3391 patients have been assessed for eligibility in 6 centres. Of those sufferers, 1347 (39.7 ) were eligible and approached for participation inside the trial and 312 (23.1 ) were randomized. The imply rate of randomization was 8.2.three patients per month. Throughout follow-up, 5 recurrent VTE events have been observed, three (1.9 ) inside the rosuvastatin group (two pulmonary embolism, 1 deep vein thrombosis) and 2 (1.3 ) within the handle group (2 pulmonary embolism) (P = 0.68). A single key arterial occasion occurred inside the rosuvastatin arm and none inside the handle arm (0.6 vs. 0 , P = 0.50). Efficacy and security clinical outcomes are summarized in Table 1. TABLE 1 Efficacy and safety clinical outcomesOutcomes Thrombotic events, n ( ) Recurrent major VTE (total) Recurrent DVT Recurrent PE Recurrent non-major VTE Arterial events (total) Myocardial infarction Stroke/TIA Acute limb ischemia Death from any bring about, n ( ) Important bleed, n ( ) 3 (1.9) 1 (0.six) two (1.3) 1 (0.6) 1 (0.six) 0 1 (0.6) 0 0 0 two (1.three) 0 2 (1.3) 0 0 0 0 0 1 (0.6) 1 (0.six) 0.68 0.50 1 0.50 0.50 1 0.50 1 1 1 Rosuvastatin (n = 155) Manage (n = 157) P valueConclusions: In conclusion, this pilot trial established feasibility of a bigger scale randomized controlled trial to decide the